Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Columbianetin SCHEMBL20356593 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1GAAABCB1 | |
| Columbianetin SCHEMBL50251 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1GAAABCB1 | |
| SCHEMBL30256774 | 0.88 | KDM4E (0.79) | KDM4EHPGDALDH1A1GAAABCB1 | |
| SCHEMBL12247775 | 0.85 | KDM4E (0.79) | KDM4EHPGDALDH1A1GAAABCB1 | |
| SCHEMBL31438609 | 0.85 | KDM4E (0.79) | KDM4EHPGDALDH1A1GAAABCB1 | |
| SCHEMBL29390971 | 0.81 | ABCB1 (1.00) | KDM4EHPGDALDH1A1GAAABCB1 | |
| Columbianadin SCHEMBL14424509 | 0.80 | KDM4E (1.00) | KDM4EHPGDALDH1A1GAAABCB1 | |
| SCHEMBL30794498 | 0.80 | KDM4E (0.74) | KDM4EHPGDALDH1A1GAAABCB1 | |
| Angelmarin SCHEMBL30443353 | 0.75 | KDM4E (0.63) | KDM4EHPGDALDH1A1GAAABCB1 | |
| Angelmarin SCHEMBL29507688 | 0.75 | KDM4E (0.63) | KDM4EHPGDALDH1A1GAAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2021-11-25 | — | — | US | disclosed |
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | NOTCH1, DNER, NOTCH2 | KDM4E 921/4885HPGD 2958/4885ALDH1A1 2580/4885 |
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | NOTCH1, DNER, NOTCH2 | KDM4E 921/4885HPGD 2958/4885ALDH1A1 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.